Valeant Pharmaceuticals International, Inc. (VRX) Stock Rating Reaffirmed by Barclays PLC


's stock had its "hold" rating restated by Barclays PLC in a note issued to investors on Thursday. They currently have a $34.00 price objective on the specialty pharmaceutical company's stock.



from Biotech News